Dublin, Jan. 17, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 342 of these are profiled in the report along with tabulation of 811 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2015 according to technologies, applications and geographical regions. Forecasts are made up to 2025. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
This was the first commercial report on this topic and published as "DNA Diagnostics" in 1995 by PJB Publications, UK. A new edition in 1997 "Molecular Diagnostics I" as well as the next edition, "Molecular Diagnostics II" in 1999, were published by Decision Resources Inc, USA. All the three versions of the reports were well received and sold widely. The report has been rewritten several times since then.
Benefits of this report:
- This report has evolved during the past 20 years, profiting from feedback by numerous readers and experts.
- The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
- Includes profiles of 343 companies, the largest number in any report on this topic.
- 600 references, cited in the report are included in the bibliography.
- The text is supplemented by 101 tables and 15 figures.
Key Topics Covered:
Part I: Technologies & Applications
0. Executive Summary
1. Introduction
2. Molecular Diagnostic Technologies
3 DNA dendrimer signal amplification
3. Biochips, Biosensors, and Nanobiotechnology
4. Proteomic Technologies for Molecular Diagnostics
5. Molecular Diagnosis of Genetic Disorders
6. Molecular diagnosis of cardiovascular disorders
7. Molecular Diagnosis of Infections
8. Molecular Diagnosis of Cancer
9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare
10. Molecular Diagnostics in Forensic Medicine and Biological Warfare
11. References
Part II: Regulations, Markets & Companies
12. Ethics, Patents and Regulatory issues
13. Markets for Molecular Diagnostics
14. Companies involved in molecular diagnostics
For more information about this report visit http://www.researchandmarkets.com/research/w4hbxl/molecular
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: In Vitro Diagnostics, Molecular Diagnostics


SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Apple Turns 50: From Garage Startup to AI Crossroads
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
First Western Ship Transits Strait of Hormuz Since Iran War Began
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 



